Join Jasper Therapeutics in-person or via live webcast for an investor event featuring Martin Metz, M.D., Professor in the Department of Dermatology and Allergy, Charité – Universitätsmedizin, Berlin, Germany, who will join company management to discuss results from the ongoing BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria (CSU). Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor.

The event will focus on BEACON study results that will be presented at the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting / World Allergy Organization (WAO) Joint Congress being held from February 28-March 3 in San Diego, California.

A live question and answer session will follow the formal presentations.